RxDoctor Payments Data

Kelly Finan, MD

Colon & Rectal Surgery · Baton Rouge, LANPI 1295940559

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Applied Medical Resources Corporation accounts for 94.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $11,654 and has fallen 97.7% since, to $268 in 2025.

$12,662in general payments, 2019–2025

Across 49 payments — averaging $258.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Applied Medical Resources Corporation$12K
  • Medtronic$240
  • Kerecis Limited$131
  • Dilon Technologies, Inc.$116
  • Innovation Technologies Inc$46
  • Merck$37
  • plus $194 from 9 others

What the payments were for

  • Consulting fees$6,75053%
  • Speaking & faculty fees$3,00024%
  • Travel & lodging$1,91015%
  • Food & beverage$1,0028%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,662 in reported general payments places this provider in the 70th percentile of 39 colon & rectal surgery providers in Louisiana.

See all colon & rectal surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$91,746
Medicare patients
237
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates62$4,336
Neomycin Sulfate27$161
Metronidazole30$57
Ibuprofen11$56

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →